P2.01-37 a Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) With Docetaxel in PTS With Previously Treated NSCLC
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1091
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV